2025/12/29-Polaris Group (TWSE: 6550) convened an extraordinary shareholders’ meeting on the morning of December 26, 2025, at which shareholders approved a proposal for a private placement of common shares for FY 2025.
Polaris Group’s Board Approves Private Placement at a Price Near Market Value Read More »
Polaris Group (TWSE: 6550) is pleased to announce that its lead drug pegargiminase (ADI-PEG 20) which is already under FDA review for a new drug application for the treatment of malignant pleural mesothelioma is also showing remarkable progress in the treatment of acute myeloid leukemia (AML). The latest encouraging data from its Phase 1 clinical trial were officially presented on December 6, 2025, at the annual meeting of the American Society of Hematology.
Phase 1 Clinical Trial Results of ADI-PEG 20 in Acute Myeloid Leukemia by Polaris Group Read More »
Genovior Biotech (“Genovior”) announced today the expansion of its sterile injectable manufacturing capacity, enabling large-scale commercial production of fully synthetic peptide medicines and specialty sterile dosage forms for global markets.
2025/11/21-GENOVIOR and MNR Therapeutics announce an non-exclusive agreement for the commercialization of Fulvestrant in the Gulf Cooperation Council (GCC) region.
2025/8/18-Polaris Group (The Company, TWSE:6550) previously adopted a rolling submission approach for regulatory filing of its Biologic License Application (BLA) for ADI-PEG 20 to the U.S. Food and Drug Administration (FDA) on November 16, 2023 (U.S. time). ADI-PEG 20 is the systemic treatment of patients with Malignant Pleural Mesothelioma (MPM) with non-epithelioid histology, in combination with a platinum agent and pemetrexed. The final portion of the BLA submission was completed on June 9, 2025 (U.S. time).
2025/7/22-Polaris Group (TWSE:6550) announces its US California subsidiary Polaris Pharmaceuticals Inc. (PPI) an exclusive licensing agreement with Bioprofarma Bagó (a fully owned subsidiary of GRUPO EMPRESARIAL BAGO) in Buenos Aires, Argentina to introduce ADI-PEG20 (ADZODI), a novel treatment for Malignant Pleural Mesothelioma (MPM) to the LATAM. This partnership is set to improve the treatment landscape by delivering innovative therapeutic solution aimed at improving patient outcomes across the region.
2025/6/9-Polaris Group (The Company, TWSE:6550) previously adopted a rolling submission approach for regulatory filing of its Biologic License Application (BLA) for ADI-PEG 20 to the U.S. Food and Drug Administration (FDA) on November 16, 2023 (U.S. time).
2025/4/15-On April 15th, 2025, Polaris Group-KY (6550) held a groundbreaking ceremony for the new plant with the expansion of 6 production lines at Zhunan. The attending guests and the ones sending their congratulations include Hsinchu Science Park Bureau, Longtai Construction, Hua Nan Bank, Taiwan Cooperative Bank, Shanghai Commercial & Savings Bank, Anxo Pharmaceutical, and many representatives from different industries. Chairman and CEO of Polaris Group Dr. Steve Hsu gave a ceremonial speech, mentioning that Polaris plans to invest a total of approximately NT$8 billion in phases to expand production capacity over the next five years (2025-2029), with the goal of reaching an annual output value of NT$100 billion with the dual engines after the full expansion with loaded capacity. The dual engine model includes (1) ADI-PEG20 (trade name ADZODI) for (a) malignant pleural mesothelioma (lung mesothelioma, MPM), (b) glioblastoma (brain cancer, GBM), leiomyosarcoma (LMS), acute myeloid leukemia (AML), and other indications (2) GLP-1 generics for diabetes, weight loss, and other indications.
2025/4/14-Polaris Group-KY (6550) announces today its US California subsidiary Polaris Pharmaceuticals Inc. (PPI) signed a distribution agreement with Er-Kim Pharmaceuticals, an international company specializing in the commercialization of novel therapies for pharmaceutical and biopharmaceutical companies. Polaris appointed Er-Kim as the exclusive partner to commercialize Pegargiminase (ADZODI) across 36 markets in the EMEA region (Central & Eastern Europe, Eurasia, North Africa and Mediterranean regions).
2025/4/14-Polaris Group-KY (6550) announces today its US California subsidiary Polaris Pharmaceuticals Inc. (PPI) signed an exclusive licensing agreement with Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group, a listed company in Saudi Arabia) to introduce ADI-PEG20 (ADZODI), a novel treatment for Malignant Pleural Mesothelioma (MPM), to the 7 markets in Saudi Arabia and the GCC region. This partnership is set to improve the treatment landscape by delivering innovative therapeutic solution aimed at improving patient outcomes across the region.
